Theralase Stock Upgraded on US OTC Market
June 12 2014 - 6:59AM
Access Wire
Toronto, Ontario / ACCESSWIRE / June 12, 2014 /
Theralase Technologies Inc.
("Theralase") (TSXV: TLT)
(TLTFF: OTC Link(R)) announced that effective June 3,
2014, its common shares, which trade in the United States Over The
Counter (OTC) market under the trading symbol TLTFF, have been
upgraded on a venue change from the Grey Market to the
OTC Link Market.
OTC Markets facilitates
electronic trading with its SEC registered Alternative Trading
System known as OTC Link(R) ATS. This system is owned by OTC
Link(R), a subsidiary company of OTC Markets Group, that is a fully
registered broker-dealer and member of FINRA. The OTCQX(R),
OTCQB(R) and OTC Pink(R) platforms traded $135 billion of
transactions in 2012 with an average daily dollar volume of $600
million, comprising 10,000 corporate securities; which includes 650
U.S. banks, 2,300 companies that report to the Securities and
Exchange Commission (SEC), 1,600 companies that pay dividends,
1,400 American Depository Receipts (ADRs) and 1,400 foreign
companies. Together these corporations boast an aggregate market
capitalization of approximately $11.6 trillion.
Roger Dumoulin-White,
President and CEO of Theralase stated that, "As Theralase continues
to execute on its strategic initiatives and accelerate our growth
in both our therapeutic and anti-cancer divisions, there is a
growing interest south of the border to invest in our common stock.
By changing venues from Grey Market to OTC Link(R), the Company is
able to provide further transparency and financial reporting to our
US based investors allowing them access to more information and
hence a greater comfort in investing in Theralase. As Theralase
delivers on its corporate milestones in both divisions in 2014 and
2015, it would be reasonable to expect the interest in acquiring
Theralase common stock to increase among US based investors,
leading Theralase to pursue full financial reporting and disclosure
to the SEC to allow an eventual listing on a major US exchange,
such as NASDAQ."
About Theralase Technologies Inc.
Theralase Technologies
Inc. ("Theralase")
(TSXV: TLT) (TLTFF: OTC
Link(R)) designs, manufactures and markets patented,
superpulsed laser technology used in eliminating pain and
destroying cancer. Theralase technology is safe and effective in
eliminating pain, reducing inflammation and accelerating tissue
regeneration in numerous nerve, muscle and joint conditions.
Theralase is developing patented Photo Dynamic Compound (PDC)
technology that is able to target and destroy cancers, bacteria and
viruses when light activated.
Additional information is
available at www.theralase.com and
www.sedar.com
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
1.866.THE.LASE (843.5273) x 225
416.699.LASE (5273) x 225
rwhite@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Theralase Technologies (TSXV:TLT)
Historical Stock Chart
From Jul 2023 to Jul 2024